advertisement
 

  Back to Ask the Diabetes Team Ask the Diabetes Team
Question:

From Watertown, Massachusetts, USA:

A family friend has a new baby diagnosed with persistent hyperinsulinemic hypoglycemia of infancy (nesidioblastosis). What is the incidence in Caucasians (specifically Italian and Irish populations)?

Answer:

Two recent Scandinavian reports put the incidence at between 1:40,000 and 1:50,000 live births, but I know of no assessments limited to Irish or Italian populations nor do there seem to be any individual population figures for the two main forms of PHHI.

DOB

Additional comments from Dr. Marco Songini:

As far as the Italian data, I'm not aware of any published or reliable source regarding the incidence of persistent hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) from my country.

MS

Additional comments from Dr. Jim Lane:

It is a very uncommon disorder in which there is continued production of insulin, despite the fact that the blood sugar is low or normal. This condition has to do with the activation of a receptor on the insulin-secreting beta cells which leaves the switch always on for insulin secretion. We are still learning a lot about this disorder. The receptor shares activity with the function of the group of hypoglycemic medications known as sulfonylureas.

JTL

DTQ-20010817162740
Original posting 4 Sep 2001
Posted to Nesidioblastosis

  
advertisement


                 
  Home Return to Top

Last Updated: Tuesday April 06, 2010 15:09:26
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.